DLA Piper launch their 2023 Global M&A Intelligence Report – Life Sciences Supplement
In June, the DLA Piper Life Sciences sector team launched the new Life Sciences supplement to their 2023 Global M&A Intelligence Report.
This report offers valuable market insights into the 2022 life sciences M&A deal landscape, complementing the 2023 global M&A intelligence report, which is now in its ninth edition.
The life sciences industry encompasses various sub-sectors, such as pharmaceuticals, medical devices, and biotech.
The supplement analyses a curated selection of international corporate life sciences transactions to identify emerging trends and developments. These findings provide valuable intelligence for industry participants exploring M&A opportunities, whether on a domestic or international scale.
The report concentrates on five major themes:
- Due Diligence (DD)
- Warranty and Indemnity (W&I) insurance
- Transaction structures
- Trade vs. Private Equity
- US vs. Rest of the World (RoW)
Read more and request the report here.
